Asthma is a genuine worldwide medical condition influencing all age gatherings, with expanding pervasiveness in many agricultural nations, rising therapy costs, and a rising weight for patients and the local area. Hypersensitive components have been involved for asthma in 50–80% of patients and these rates are additionally relevant to patients with serious asthma. This examination planned to survey clinical results of omlizumab treatment; asthma control, decrease of asthma seriousness and compounding and specific consideration regarding medical clinic, ICU stays and oral steroid organization. Planned associate examination directed on 32 subjects with serious unfavorably susceptible uncontrolled bronchial asthma. Omalizumab was given subcutaneous, at regular intervals or month to month as indicated by changed necessities while past asthma medicine not diminished or halted. Asthma control appraisal, asthma seriousness appraisal, medical clinic stay, ICU stay, and oral steroid organization prior to beginning omalizumab and 1, 3, 6 months subsequent to beginning omalizumab therapy were assessed and recorded. Following a half year of omalizumab organization their was considerable improvement of FEV1/FVC and FEV1 with critical decrease of uncontrolled cases, and huge decrease in severity.Likewise generous improvement of asthma intensifications, medical clinic affirmations, ICU confirmations and recurrence of oral steroid organization following a half year of omalizumab organizations. Omalizumab showed great outcomes for its utilization in patients with serious hypersensitive asthma, and aided in progress of lung capacities, asthma control , asthma seriousness, and decrease of asthma intensifications , ICU confirmations and use of fundamental steroid.